A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Sponsor decision
The register will no longer be maintained on a prospective basis
Low enrollment and PI retired.
Lack of research personnel
Following review of accumulated safety data from DISCOVER and real-world use of F/TAF, the sponsor determined that the long-term safety of F/TAF had been demonstrated and no further safety monitoring within the study was required.
Sponsor Decision
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
Difficulties in recruiting patients
Study is suspended due to lack of funds. Will resume as soon as funding is secured.
Study withdrawn before opening to accrual.
Enrollment Goal Met
14 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| ZHEJIANG JUTAI PHARM | BRIVARACETAM | 2026-09-08 |
| HETERO LABS LTD V | IBRUTINIB | 2026-09-08 |
7.1% of the last year's EMA authorisations were conditional.
None authorised this period.
2 new · 0 resolved · 103 currently active.
| Newly reported shortage | Posted |
|---|---|
| Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution | 2026-09-10 |
| Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection | 2026-09-09 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 85,122 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Cairo University | 4,842 |
| Assiut University | 4,841 |
| GlaxoSmithKline | 3,636 |
| National Cancer Institute (NCI) | 3,553 |
| Assistance Publique - Hôpitaux de Paris | 3,552 |
| AstraZeneca | 3,483 |
| Pfizer | 3,305 |
| Mayo Clinic | 3,245 |
| M.D. Anderson Cancer Center | 3,026 |
| Novartis Pharmaceuticals | 2,702 |
| National Taiwan University Hospital | 2,601 |
| Massachusetts General Hospital | 2,572 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,440 |
| Boehringer Ingelheim | 2,290 |
| University of California, San Francisco | 2,156 |
| Riphah International University | 2,153 |
| Stanford University | 2,150 |
| Merck Sharp & Dohme LLC | 2,146 |
| Eli Lilly and Company | 2,087 |
| Hoffmann-La Roche | 2,084 |
| Duke University | 2,052 |
| Memorial Sloan Kettering Cancer Center | 1,950 |
| Ain Shams University | 1,894 |
| Seoul National University Hospital | 1,893 |
| Hospices Civils de Lyon | 1,844 |
| Condition | Trials |
|---|---|
| breast cancer | 11,878 |
| obesity disorder | 9,671 |
| type 2 diabetes mellitus | 9,199 |
| chronic pain syndrome | 8,868 |
| cancer | 8,341 |
| HIV infectious disease | 8,247 |
| COVID-19 | 7,650 |
| non-small cell lung carcinoma | 6,431 |
| hypertensive disorder | 6,169 |
| diabetes mellitus | 6,162 |
| colorectal cancer | 6,076 |
| cerebrovascular disorder | 6,075 |
| coronary artery disorder | 5,978 |
| prostate cancer | 5,888 |
| depressive disorder | 5,878 |
| cardiovascular disorder | 5,634 |
| anxiety disorder | 4,978 |
| heart failure | 4,938 |
| injury | 4,522 |
| Parkinson disease | 4,472 |
| asthma | 4,447 |
| cognitive disorder | 4,222 |
| lung cancer | 4,088 |
| neuralgia | 3,912 |
| benign essential hypertension | 3,890 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,239 |
| paclitaxel | 5,614 |
| isoniazid | 5,380 |
| prednisolone | 5,341 |
| cyclophosphamide | 5,144 |
| ropivacaine | 4,929 |
| dexamethasone | 4,839 |
| bevacizumab | 4,674 |
| cisplatin | 4,517 |
| lidocaine | 3,670 |
| aspirin | 3,454 |
| gemcitabine | 3,220 |
| bupivacaine | 3,182 |
| pembrolizumab | 3,024 |
| metformin | 3,006 |
| desoxycorticosterone acetate | 2,994 |
| sitagliptin and metformin hydrochloride | 2,979 |
| rituximab | 2,961 |
| meprednisone | 2,850 |
| sitagliptin metformin hydrochloride | 2,791 |
| dapagliflozin metformin hydrochloride | 2,788 |
| linagliptin and metformin hydrochloride | 2,778 |
| docetaxel | 2,776 |
| fluorouracil | 2,750 |
| alogliptin and metformin hydrochloride | 2,720 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,096 | 862 | 900 |
| AstraZeneca | 1,022 | 552 | 809 |
| Pfizer | 1,177 | 710 | 663 |
| Novartis Pharmaceuticals | 512 | 840 | 738 |
| Boehringer Ingelheim | 1,073 | 321 | 400 |
| Merck Sharp & Dohme LLC | 702 | 552 | 741 |
| Eli Lilly and Company | 836 | 538 | 551 |
| Hoffmann-La Roche | 493 | 481 | 570 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Citalopram Hydrobromide | 2026-09-16 |
| Phentolamine Mesylate | 2026-09-25 |
| Atogepant | 2026-09-28 |
| Miglustat | 2026-09-28 |
| Technetium Tc-99m Labeled Carbon | 2026-09-29 |
| Patiromer Sorbitex Calcium | 2026-10-02 |
| Dexamethasone | 2026-10-03 |
| Risdiplam | 2026-10-03 |
| Afamelanotide | 2026-10-08 |
| Binimetinib | 2026-10-11 |
| Acetaminophen; Ibuprofen Sodium | 2026-10-17 |
| Tenapanor Hydrochloride | 2026-10-17 |
| Pilocarpine Hydrochloride | 2026-10-17 |
| Edoxaban Tosylate | 2026-10-18 |
| Treprostinil Diolamine | 2026-10-18 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.